RT Journal Article SR Electronic T1 90Y-Ibritumomab Tiuxetan Consolidation After Autologous Stem Cell Transplantation Improves Survival of Patients with Intermediate-/High-risk Diffuse Large B-cell Lymphoma Not Responding Adequately to First-line Treatment JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 5121 OP 5125 VO 34 IS 9 A1 PATRIZIA MONDELLO A1 VINCENZO PITINI A1 CARMELA ARRIGO A1 ENRICO DERENZINI A1 MICHAEL MIAN YR 2014 UL http://ar.iiarjournals.org/content/34/9/5121.abstract AB Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma entity whose prognosis for high-risk patients is poor. Aggressive salvage treatments to improve patient outcome have been unsatisfactory. Therefore, we evaluated the efficacy of yttrium-90-ibritumomab tiuxetan (Zevalin®; 90Y-IT) consolidation after early salvage chemotherapy with autologous stem cell transplantation. Thirty-seven patients with intermediate-high risk DLBCL not in complete remission (CR) after three cycles of rituximab, cyclophosphomide, doxorubicin, vincristine and prednisone (R-CHOP) were assessed retrospectively. After early salvage treatment, 70% achieved CR and 30% partial remission. Twenty patients underwent additional consolidation with 90Y-IT. During the 3-year follow-up, 50% in the 90Y-IT-treated group experienced relapse compared to 82.3% in the other cohort (p=0.002). Progression- and disease-free survival were significantly longer in the 90Y-IT group. However, probably due to the relatively short follow-up period, no difference in overall survival was observed. 90Y-IT consolidation after early salvage chemotherapy improves treatment responses and reduces the percentage of relapses without significant additional toxicities.